Under construction – not a live service
Sign in
WithdrawnPhase 2

ADI-PEG20, Obesity and Prediabetes

Key facts

Who runs it
Washington University School of Medicine
Where
St Louis, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 2
Started
1 Apr 2024
Ended
1 May 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • ADI-PEG20
  • Placebo
Record updated
7 November 2024
Why it stopped
Unable to obtain study drug to be able to perform the study

Who can take part

Age
18 years to 22 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • age: ≥18 and ≤22 years
  • BMI 25.0 - 44.9 kg/m2
  • Prediabetes, defined as fasting plasma glucose of ≥100 mg/dL, or HbA1C ≥5.7%, or HOMA-IR ≥2.5

Who cannot take part

  • Taking dietary supplements or medications known to affect our study outcomes
  • Metallic implants, which would preclude MRI
  • Intolerance or allergies to ingredients in ADI-PEG20 or placebo
  • Evidence of significant organ system dysfunction or diseases,
  • HbA1C ≥6.5%

Where in United States

  • Washington University School of MedicineSt Louis, United StatesNo longer taking part

About the trial

What the trial wants to find out

Th purpose of this study is to determine whether ADI-PEG20 (PEGylated arginine deiminase), an arginine catabolizing enzyme preparation, improves insulin sensitivity, mitochondrial respiration, and energy utilization in adolescents with prediabetes.

The 2 groups in the trial

  • ADI-PEG20Treatment being tested

    ADI-PEG20 (ADI-PEG20 is arginine deiminase (ADI) conjugated to polyethylene glycol (PEG) of 20,000 molecular weight) will be weekly intramuscularly at a dose of 18 mg/m2 body surface area/week for 8-week.

  • PlaceboPlacebo, for comparison

    Will be weekly intramuscularly for 8-week

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Randomized Trial Using ADI-PEG20 to Improve Insulin- and Energy Homeostasis in Adolescents With Obesity
Record updated
7 November 2024